e

Products: Alicaforsen

In March 2007, Atlantic Healthcare signed an exclusive licensing agreement with Isis Pharmaceuticals, Inc (NASDAQ:ISIS) in which it acquired the global rights to late-stage anti-inflammatory, antisense drug programmes

 Atlantic Healthcare's acquired clinical programmes for alicaforsen target inflammatory bowel diseases. Clinical data on alicaforsen used in these programmes, demonstrates significant safety, efficacy, tolerability and durability benefits, with the potential for clear and strong product differentiation
   
   

In December 2007, Atlantic Healthcare announced an agreement with Sigma Pharmaceuticals’ Australian subsidiary Orphan Australia Pty Ltd, a hospital focused specialist sales and marketing group, for the commercialisation of two of its Phase III programmes in the Southern Hemisphere

 Atlantic Healthcare is initially targeting the treatment of pouchitis with alicaforsen, for which there is no approved treatment. Having been granted Orphan Drug status in the USA and Europe and Fast Track Approval by the US Food and Drug Administration, Atlantic Healthcare intends to commence sales of alicaforsen in Europe ahead of its pivotal Phase III clinical programme, under various “Named Patient Supply” regulations

Atlantic Healthcare is also targeting the use of alicaforsen for the treatment of other inflammatory bowel diseases including left-sided (distal) colitis

Alicaforsen has a number of potential advantages if current data are born out in larger scale trials.  These include the tolerability of a topical agent and potential efficacy through a novel mode of action

                          *If the data seen in Phase II clinical studies are born out in pivotal studies and/ or clinical practice
   
   
 
 

Terms & Conditions
© Atlantic Healthcare Limited, 2011.  All Rights Reserved.